Evidence map›Paper›PMID 30375717›Full record

ArticleCancer science2019

Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.

Akifumi Uchida, Naohiko Seki, Keiko Mizuno, Shunsuke Misono, Yasutaka Yamada, Naoko Kikkawa, Hiroki Sanada, Tomohiro Kumamoto, Takayuki Suetsugu, Hiromasa Inoue

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Cells · 2020
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Involvement of Dual Strands ofInternational journal of molecular sciences · 2019
    Article
  18. Article
  19. Regulation ofCancers · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Akifumi UchidaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-8038-6377
Naohiko SekiDepartment of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keiko MizunoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Shunsuke MisonoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Yasutaka YamadaDepartment of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID http://orcid.org/0000-0002-0070-1590
Naoko KikkawaDepartment of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroki SanadaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Tomohiro KumamotoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Takayuki SuetsuguDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Hiromasa InoueDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Kagoshima University · JPChiba University · JP

Funding

KAKENHI grants 16K11224KAKENHI grants 17K09660KAKENHI grants 18K09338
6 · The paper itself

Abstract

The prognosis of patients with advanced-stage lung squamous cell carcinoma (LUSQ) is poor, and effective treatment protocols are limited. Our continuous analyses of antitumor microRNAs (miRNAs) and their oncogenic targets have revealed novel oncogenic pathways in LUSQ. Analyses of our original miRNA expression signatures indicated that both strands of miR-144 (miR-144-5p, the passenger strand; miR-144-3p, the guide strand) showed decreased expression in cancer tissues. Additionally, low expression of miR-144-5p significantly predicted a poor prognosis in patients with LUSQ by The Cancer Genome Atlas database analyses (overall survival, P = 0.026; disease-free survival, P = 0.023). Functional assays revealed that ectopic expression of miR-144-5p and miR-144-3p significantly blocked the malignant abilities of LUSQ cells, eg, cancer cell proliferation, migration, and invasion. In LUSQ cells, 13 and 15 genes were identified as possible oncogenic targets that might be regulated by miR-144-5p and miR-144-3p, respectively. Among these targets, we identified 3 genes (SLC44A5, MARCKS, and NCS1) that might be regulated by both strands of miR-144. Interestingly, high expression of NCS1 predicted a significantly poorer prognosis in patients with LUSQ (overall survival, P = 0.013; disease-free survival, P = 0.048). By multivariate analysis, NCS1 expression was found to be an independent prognostic factor for patients with LUSQ patients. Overexpression of NCS1 was detected in LUSQ clinical specimens, and its aberrant expression enhanced malignant transformation of LUSQ cells. Our approach, involving identification of antitumor miRNAs and their targets, will contribute to improving our understanding of the molecular pathogenesis of LUSQ.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticAgedAged, 80 and overCarcinoma, Squamous CellCell Line, TumorFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMicroRNAsMiddle AgedMonosaccharide Transport ProteinsMyristoylated Alanine-Rich C Kinase SubstrateNeuronal Calcium-Sensor Proteinsfrequenin calcium sensor proteinsMARCKS protein, humanMicroRNAsMIRN144 microRNA, humanMonosaccharide Transport ProteinsMyristoylated Alanine-Rich C Kinase SubstrateNeuronal Calcium-Sensor ProteinsNeuropeptidesSLC45A1 protein, humanlung squamous cell carcinomamicroRNAmiR-144-3pmiR-144-5pNCS1

Identifiers

PMID30375717
PMCPMC6317942
OpenAlexW2899402835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.